European CHMP recommends approval of fedratinib (Inrebic) for treatment of primary myelofibrosis and of myelofibrosis secondary to polycythaemia vera or essential thrombocythaemia
Fedratinib is an oral protein kinase inhibitor with antineoplastic activity linked to selective inhibition of the Janus associated kinases. Reported benefits include ability to reduce size of the spleen and symptomatic treatment.
Source:
European Medicines Agency